|
|
Jae-Hyun Kim
President/Korea Advanced Institute of Science and Technology, Chemistry
1979 Bachelor, Seoul National University / Chemistry Education
1981 Master, Korea Advanced Institute of Science and Technology / Chemistry
1989 Ph.D, Korea Advanced Institute of Science and Technology / Chemistry
2011~Present President, KRICT
1983~Present Professor, Kongju National University
1998~2001 Vice President, Office of Planning, Kongju National University
1981~1983 Chief Official of Industrial Policy, Ministry of Science and Technology
1993~1994 Exchange Professor, University of Wisconsin at Madison
2001~2005 Member, Editorial Review Board of Journal of Chemistry education,
American Chemical Society
2002~2003 Chair, Editorial Review Board of Chemical Education, Korean Chemical Society
2005~2006 Member, Permanent Consulting Council of Nuri Project,
Ministry of Education and Human Resources Development
2006~2010 President, Kongju National University
2008~2010 Auditor, Korean Council of University Education | |
|
|
Stephen Sung-Han Yoo
Branch Chief/MRTB, RRP, NCI, NIH
1983~1987 B.S. Biology, Yonsei University, Seoul, Korea
1988 - 1994 Ph.D. Biochemistry and Biophysics Texas A&M University, College Station, Texas
1988~1990 Teaching Assistant, Biochemistry and Biophysics,
Texas A&M University, College Station, Texas
1990~1994 Research Assistant, Biochemistry and Biophysics
Texas A&M University, College Station, Texas
1994~1995 Postdoctoral fellow, Chemistry and Biochemistry
University of Colorado, Boulder, Colorado
1996~1999 Postdoctoral fellow, Institute of Molecular Medicine and Genetics,
Medical College of Georgia, Augusta, Georgia
1999 Instructor, Institute of Molecular Medicine and Genetics, Medical College of Georgia, Augusta, Georgia
1999~2001 Assistant Professor, Department of Radiation Medicine, Georgetown University, Washington, DC
2002~2004 Scientific Review Officer, NCI/NIH
2005~2008 Program Director, NCI/NIH
2008~Present Branch Chief, MRTB/RRP/NCI/NIH | |
|
|
Michele Liuzzi
CEO/Institut Pasteur Korea
1980 B.S. in Chemistry, University of Liège
1984 Ph.D. in Biological Chemistry, University of Liège
Thesis: Dosage des sites AP. Application à l'études des enzymes de réparation du DNA exposé aux radiations ionisantes
1984~1985 NCI Postdoctoral Fellow, Chalk River Nuclear Laboratories, Canada
1985~1989 AHFMR Postdoctoral Fellow, Cross Cancer Institute, Canada
1989~2004 Group Leader/Disease Area Head RSV, Group Leader HCV Exploratory,
BoehringerIngelheim Ltd., Canada
2004~2009 Executive Director Virology, Idenix Pharmaceuticals Inc., Italy
2011~2013 Executive Director, Early Discovery Program, Institut Pasteur Korea
2013~present CEO, Institut Pasteur Korea
- A potent peptidomimetic inhibitor of HSV ribonucleotidereductase with antiviral activity in vivo. Nature,372, 695-698 (1994).
- Herpes Simplex virus helicase-primase inhibitors are active in animal models of human disease. Nature Medicine8, 386-391 (2002). | |
|
|
Sung-Joo Lee
Head, AP Research, Therapeutic strategic Unit AP R&D/Sanofi
Sung-Joo Lee, Ph,D is the Head of AP Research as well as Korea R&D Leader of Therapeutic Strategic Unit of Asia Pacific R&D. He is responsible for developing open R&D strategy for research and implementing the overall TSU strategy in Asia. Since 2010, he is building an open innovation network with academic and biotech partners. Collaborations initiated include Institute Pasteur Korea, Oncoventure, Bioneer and LegoChemBio. Sung-Joo obtained his Ph,D at UC Berkeley in 2003 and conducted postdoctoral research at Stanford.
Before joining Sanofi in 2010, Sung-Joo was leading R&D collaboration discussions with various partners in academia and pharma, and has established understanding of the innovation landscape in Korea. His industry career started at as a computational biologist, providing modeling support to drug discovery projects including diabetes, Alzheimer’s and HBV inhibitors. Upon joining R&D strategic planning at LG, he calculated risk-adjusted NPV of R&D projects and proposed a long term strategy to management.
Sung-Joo has presented in major biopartnering meetings and published scientific articles in biological modeling. | |
|
|
Jee-Woong Son
Head of R&D/Hanmi Pharmaceuticals
2006 Korea University Business School Seoul, Korea Master of Business Administration
2001 Seoul National University Graduate School Seoul, Korea Ph.D. in Medical Science,
majored in Genetics of Asthma
1997 Seoul National University Master of Philosophy in Medical Science,
majored in Internal Medicine (Genetics of Asthma)
1989 Seoul National University College of Medicine Seoul, Korea Medical Doctor
2011~Present Head of R&D, Hanmi Pharmaceuticals
2010 Senior VP, Clinical Development and Licensing, Hanmi pharmaceuticals
2009~2010 Senior Medical Director and Asia Alliance Manager, AstraZeneca
2007~2009 Head of Clinical Science Department, R&D Clinical Division,
AstraZeneca Japan
2007~2009 Clinical Lead of Asia Disease Area Team of Oncology Therapeutic Area,
AstraZeneca
2002~2007 Marketing Company Medical Director, AstraZeneca Korea
2003~2005 Regional Study Team Leader of ACRU-EA, AstraZeneca Clinical
Research Unit-East Asia
2010~Present International Relations Manager, Korean Society of Biochemistry
and Molecular Biology
2010~Present Auditor, Korean Society of Pharmaceutical Medicine
2005~2007 Director of Education, Korean Society of Pharmaceutical Medicine
2005~2006 Chair of Scientific Committee, ICPM 2006 Organizing Committee
(ICPM : International Conference on Pharmaceutical Medicine)
2001~2002 Executive Secretary, World Asthma Day Project Office
(Korean organization for cooperation with GINA, Global Initiative for Asthma)
1999~2002 Assistant Professor of Hallym University College of Medicine /
Head of the division of allergy and respiratory medicine of the Hospital,
Hallym University Kangdong Sacred Heart Hospital (Seoul)
2000~2002 Chief Director of Allergy and Clinical Immunology, Hallym University
Kangdong Sacred Heart Hospital (Seoul)
2006~Present Consulting Professor, Ajou University Clinical Trial Center (Suwon, Korea) | |
|
|
Calro Incerti
Sr. Vice President, Head Global Medical Affairs/Genzyme Corporation
Dr. Incerti serves as Officer of Genzyme Corporation, where he oversees Global Medical Affairs , which includes Medical Operations, Global Regulatory Affairs and Compliance, Global Patient Safety and Risk Management, Evidence Value Development/Health Economics and Outcomes Research and Global Policy.
The mission of the Global Medical Affairs Group is to facilitate and enable patient access for Genzyme’s products through an integrated global strategy. GMA functional area operates as a continuum to enhance the value proposition of Genzyme’s products, thus ensuring a successful “product journey” from the development stage through the administration of therapy.
Dr Incerti is a Board Certified Endocrinologist, who started his career in the medical profession as a staff member and then as Associate Professor at the Department of Endocrinology of Modena University Hospital in Italy. He joined Genzyme in 1992 as Medical Director Europe and then was promoted to Senior Vice President Biomedical and Regulatory Affairs Europe.
In his tenure he was responsible for the development of all of the Genzyme products in the rare disease field, with specific focus on Lysosomal Storage Disorders. This development culminated in the successful approval in Europe of what is considered the first pre-orphan drug (Cerezyme for Gaucher disease) and in the first officially approved orphan drug (Fabrazyme for Fabry disease). In 2003 he assumed the responsibility for the whole EU R&D group as Head Research & Development Europe, which then included also Latin America. Dr Incerti has also served as Chairman of the Board of Directors of Genzyme Srl in Italy and of Genzyme Europe BV in The Netherlands.
He is currently member of the Board of EBE (European Biotechnology Enterprises), member of the Board of EFPIA (European Federation of Pharmaceutical Industries and Associations) and Vice Chairman of the Governing Board of IMI (Innovative Medicine Initiative), a Joint Undertaking between the EU Commission and EFPIA, which oversees the management of EU research funds for a total of 7 Billion Euro.
Dott. Incerti is a founding member and part of the IRDiRC (International Rare Disease Research Consortium), an international group which aims to foster the research and development of therapeutics for rare diseases. | |
|
|
Soon-Myung Paik
Newilhan Distinguished Professor/Severance Biomedical Science Institute Yonsei University College of Medicine
Dr. Soonmyung Paik is a pathologist with training in molecular biology. He was the recipient of the 2010 Susan Komen Foundation Brinker Award for Scientific Distinction for Clinical Science. He graduated from Yonsei University College of Medicine, Seoul, Korea in 1981 and received his residency training in the USA. After his residency, he joined Dr. Marc Lippman’s group at the National Cancer Institute as a post-doctoral fellow and worked with him at the Lombardi Cancer Center, Georgetown University, Washington DC as a faculty member until 1996 when he joined The National Surgical Adjuvant Breast and Bowel Project (NSABP) in Pittsburgh, PA, USA as the Director of the Division of Pathology. From 2009 to 2012 he had a joint appointment as the Distinguished Scientist in Medicine and the Director of the Samsung Cancer Research Institute, Seoul, Korea. He is a member of the NCI Breast Cancer Steering Committee and Program for Assessment of Cancer Clinical Testing.
Dr Paik’s main research interest is in developing predictive markers for treatment response in breast cancer and development of new trial method. In 2004 his lab, in collaboration with Genomic Health Inc, has developed a multigene based test called OncotypeDx that is used to predict prognosis and response to chemotherapy in node-negative hormone-receptor-positive breast cancer. This collaboration also led to development of OncotypeDx assay for colon cancer.
He has demonstrated that HER2 positive tumors are more responsive to doxorubicin containing regimen and thus established a baseline regimen for this subset of breast cancer. He contributed to the design and conduct of clinical trials of trastuzumab. He has also been instrumental in improving the quality of HER2 testing in the pathology community through establishment of ASCO/CAP Guideline for HER2 testing. He has demonstrated trastuzumab benefit in HER2 negative patients which led to NSABP trial B-47. His gene expression profiling work for NSABP B-27 trial led to development of "post-neoadjuvant trial" concept which is now implemented in NSABP B-5, testing post-neoadjuvant TDM1 in HER2 positive breast cancer. His mutation profiling work for colon cancer led to development of NSABP NGame phase II trial platform for colon cancer. | |
|
|
Dae-Kyong Kim
Chair/the Evaluation Committee for Life & Welfare, National Science & Technology Commission in Korea
1983 Bachelor of Science in Pharmacy, College of Pharmacy, Seoul National University, Seoul, Korea
1986 MS, Graduate School, Seoul National University
1990 PhD, Faculty of Pharmaceutical Science, Graduate School, University of Tokyo, Tokyo, Japan
1994~present Professor, Associate Professor, Assistant Professor of Biochemical Toxicology, Department of Environmental & Health Chemistry, College of Pharmacy,
Chung-Ang University
2009~present Vice President of The Pharmaceutical Society of Korea
Chief Vice President of The Korean Society of Food Hygiene and Safety
Vice President of Korean Human Proteome Organization
2013~present Chair of the Evaluation Committee for Life & Welfare,
National Science & Technology Commission in Korea
1990~1991 Instructor, Department of Life Science, Pohang University, Pohang, Korea
1991~1994 Associate Research Fellow, Institute of Massachusetts General Hospital,
Harvard Medical School, Boston, USA
1992~1994 Paul Dudley Fellowship Researcher, American Heart Association, USA
2005~present Member of IBC Top 100 Scientists
2006~present Member of Leading Scientists of the World from IBC
2006~present Member of Marquis Who’s Who
2007~present Member of President’s Citation from ABI
2009~present Commissioner, National Research Facilities & Equipment Center
2009~2009 Consulting Commissioner, Consulting Committee for Pharmacy Education,
Ministry of Education, Science & Technology of Korea
2010~present Member of the Council Review Board for Health Technology Policy,
Ministry of Health & Welfare of Korea
2009~2012 Dean, College of Pharmacy, Chung-Ang University
2009~2012 Dean, Graduate School of Food & Drug Administration, Chung-Ang University
2009~2012 Chairman of the Board of Korean Association of Pharmacy Education in Korea
2013~present Chairman of Life & Welfare Division of Evaluation Committee for
National Science & Technology, Prime Minister’s Office
2013~present Chief Vice President of The Korean Society of Food Hygiene and Safety | |
|
|
Seok-Jin Chung
Director, Bio&Nano Technology Division/Ministry of Trade, Industry & Energy
Seoul National University Bachelor of Arts
Georgetown University Master of Arts
2011~2012 Director, Northeast Industry Cooperation Division
Ministry of Knowledge Economy
2013~Present Director, Bio&Nano Technology Division
Ministry of Trade, Industry & Energy | |
|
|
Young-Joo Hur
Director, Division of Emergency Healthcare and Preparedness/Ministry of Health & Welfare
1995~1996 Instructor, Department of Preventive Medicine, College of Medicine, Yonsei University, Seoul, Korea
1997~1999 Deputy Director, Division of Communicable Diseases Control,
Ministry of Health & Welfare
2000~2002 Epidemic Intelligence Service Officer, US CDC/NIP/VSD/VAERS, Atlanta, GA, USA
* 911 and Anthrax investigation, Smallpox First Response Team
2002~2003 Deputy Director, Division of Caner Policy, Ministry of Health & Welfare
2004~2006 Director, Division of Epidemic Investigation, Ministry of Health & Welfare
2007~2008 Director, Division of International Cooperation, Ministry of Health & Welfare
2008~2009 Director, Division of FTAs and Trade, Ministry of Health & Welfare
2010~Present Director, Division of Emergency Healthcare and Preparedness,
Ministry of Health & Welfare | |
|
|
Yo-Up Lim
Director, Future Technology Division/Ministry of Science, ICT and Future Planning (MSIP)
1987 Whimoon High School
1987~1993 B.S. Department of Management, Korea University, Korea
2003~2005 M.S. Thunderbird Graduate School of International Management, U.S
2009~2010 Director, Convergence Technology Division, Ministry of Education,
Science and Technology(MEST)
2010~2010 Director, e-Learning Support Division, MEST
2011~2011 Director, Graduate School System Division, MEST
2011~2012 Director, Fundamental Research Division, MEST
2012~2013 Institut Pasteur, France
2013~Present Director, Future Technology Division, Ministry of Science, ICT and Future Planning (MSIP) | |
|
|
Jae-Du Ha
Director, Division of Drug Discovery Research/Korea Research Institute of Chemical Technology
1980-1987 Pusan National University, B.S. Chemistry
1995-1999 The University of Alabama, Ph.D. Organic Chemistry
1987~Present Research Chemist, KRICT
1993~2005 Senior Researcher, KRICT
2005~Present Principal Researcher, KRICT
2011~Present Director, Division of Drug Discovery Research, KRICT
2012~Present Adjunct Professor, Graduate School of New Drug Discovery and Development, ChungNam National University | |
|
